Condition (MeSH)
Nut Hypersensitivity
ClinicalTrials.gov lists 33 trials for Nut Hypersensitivity or a narrower condition beneath it. Alladapt Immunotherapeutics, Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
33 of the 33 trials are tagged with Nut Hypersensitivity itself; the rest are tagged with a narrower condition beneath it.
When did Nut Hypersensitivity trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2024 | 1 |
| 2023 | 6 |
| 2022 | 2 |
| 2021 | 6 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nut Hypersensitivity trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 4 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Not applicable | 13 |
| Observational | 11 |
How many Nut Hypersensitivity trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Completed | 15 |
| Terminated | 2 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Nut Hypersensitivity trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alladapt Immunotherapeutics, Inc. | 2 |
| Bayside Health | 1 |
| Candid Therapeutics | 1 |
Which drugs are being tested for Nut Hypersensitivity? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Trichuris Suis Ova | 1 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Walnut Protein Powder | 1 |
| Cashew sublingual immunotherapy | 1 |
| Open-label Walnut Protein Powder | 1 |
| Administration of wine fined with potential food allergens | 1 |
| Walnut Protein Flour | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Nut Hypersensitivity trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Systemic allergic reaction | 3 | 1 |
| Anaphylaxis | 2 | 1 |
| Sports-related concussion | 2 | 1 |
| Emergency room visit after baseline food challenge | 1 | 1 |
| Sports-related injury | 1 | 1 |
Which publications cover Nut Hypersensitivity? (25)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy of cashew nut protein immunotherapy: protocol for a single-centre randomised controlled trial in a Polish paediatric population. | BMJ open | 2025 | Yes |
| Trends in allergen-reactive CRTH2+ T cells and TARC associated with successful outcomes in a phase 2 cashew oral immunotherapy study. | Frontiers in immunology | 2025 | Yes |
| TreEAT trial: Protocol for a randomized controlled trial investigating the efficacy and safety of early introduction of tree nuts for the prevention of tree nut allergy in infants with peanut allergy. | Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology | 2023 | Yes |
| Development of peanut, sesame and tree nut allergy in Polish children at high risk of food allergy: a protocol for a cross-sectional study. | BMJ open | 2023 | Yes |
| Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study). | Allergy | 2022 | Yes |
Showing 5 of 25 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.